Roivant Sciences Ltd. Share Price & Technical Analysis
ROIV · $29.55 (-1.37%)
Healthcare / Biotechnology
$29.55
-1.37%
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease,…
Price chart
Seasonality
May has 3 positive and 2 negative years (last 5 years shown)
4% return in May, -2% avg return in past 3 year May month.
35% return in 2026, 43% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 0% | 34% | -3% | 1% | 4% | – | – | – | – | – | – | – | 35% |
| 25 | -7% | -2% | -6% | 15% | -5% | 3% | 2% | 5% | 26% | 32% | 5% | 5% | 73% |
| 24 | -11% | 13% | -9% | 4% | -5% | 2% | 4% | 13% | -6% | 1% | 9% | -7% | 8% |
| 23 | 2% | -2% | -9% | 18% | 6% | 12% | 19% | -3% | 1% | -26% | 12% | 17% | 47% |
| 22 | -33% | -9% | -25% | -24% | 19% | -5% | 0% | -10% | -11% | 59% | 4% | 38% | 3% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Strong · Uptrend
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising lipid nanoparticle (LNP) platform and ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$21.09B
P/E ratio
—
52W high
$32.79
52W low
$10.59
Volume
20,72,720
Beta
1.14
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Roivant Sciences Ltd. share price today?
- Roivant Sciences Ltd. (ROIV) last traded around $29.55 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does ROIV have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for ROIV. Download the app for real-time alerts.
- How can I analyze Roivant Sciences Ltd. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.